Companies › Sunshine Lake Pharma
10 active drug programs in 13 registered trials: 7 Phase 1, 3 Phase 3, 3 Phase 2; Oncology, Other, Respiratory, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HEC585 | – | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | Dec 2026 |
| Larotinib EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Esophageal Cancer | Aug 2027 |
| Clifutinib Besylate (HEC73543) FLT3-ITD inhibitor | FLT3 | Phase 3 | Leukemia, Acute Myeloid (AML); Acute Myeloid Leukemia, Adult | Nov 2027 |
| Mitizodone Phosphate tablets unclear mechanism for major depressive disorder | – | Phase 2 | Depressive Disorder, Major | Jul 2027 |
| HEC169584 | – | Phase 1 | Non - Alcoholic Steatohepatitis | Dec 2026 |
| HEC-007 injection | – | Phase 1 | Healthy Subjects | Dec 2026 |
| HEC-151 Injection | – | Phase 1 | Healthy Adult Male | Dec 2026 |
| HECN30227 injection | – | Phase 1 | HBV Infection | Apr 2027 |
| HEC-921 | – | Phase 1 | Advanced Malignant Solid Tumors | May 2028 |
| HEC169096 | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05451602 | HEC169096 | Phase 1 | Advanced Solid Tumor | Oncology | Sep 2025 |
| NCT05060822 | HEC585 | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Dec 2026 |
| NCT05139719 | HEC585 | Phase 2 | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | Respiratory | Dec 2026 |
| NCT07099118 | HEC169584 | Phase 1 | Non - Alcoholic Steatohepatitis | Gastroenterology | Dec 2026 |
| NCT07102251 | HEC-007 injection | Phase 1 | Healthy Subjects | Other | Dec 2026 |
| NCT07376200 | HEC-151 Injection | Phase 1 | Healthy Adult Male | Other | Dec 2026 |
| NCT07771140 | HECN30227 injection | Phase 1 | HBV Infection | Infectious disease | Apr 2027 |
| NCT04984512 | Mitizodone Phosphate tablets | Phase 2 | Depressive Disorder, Major | Psychiatry | Jul 2027 |
| NCT04415853 | Larotinib | Phase 3 | Esophageal Cancer | Oncology | Aug 2027 |
| NCT05586074 | Clifutinib Besylate (HEC73543) | Phase 3 | Leukemia, Acute Myeloid (AML) | Oncology | Nov 2027 |
| NCT05133882 | Clifutinib Besylate (HEC73543) | Phase 1 | Acute Myeloid Leukemia, Adult | Oncology | Dec 2027 |
| NCT07824934 | HEC-921 | Phase 1 | Advanced Malignant Solid Tumors | Oncology | May 2028 |
| NCT07082842 | HEC585 | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Jan 2031 |
Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical HC Biopharma Jiangsu Aosaikang Pharmaceutical Jiangsu Hansoh Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.